• Aytu Biopharma highlighted commercial focus on complex CNS conditions, centered on major depressive disorder and ADHD.
• Presentation positioned EXXUA (gepirone) extended-release tablets as a first-in-class MDD treatment, citing efficacy from two eight-week, randomized, placebo-controlled trials.
• Orange Book patent protection cited through late 2030, with Hatch-Waxman new chemical entity exclusivity through 9/28.
• Launch update showed EXXUA total prescriptions rising to 1,912 in Apr-26 from 546 in Dec-25, with shipments increasing to 920 from 43 over same period.
• Aytu RxConnect patient access program described as covering more than 1,000 pharmacies nationwide, aimed at improving access, adherence, and prescription pull-through across portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.